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Abstract
The mechanism by which cancer mediates muscle atrophy has been delineated in the past 3
decades, and includes a prominent role of tumor-derived cytokines, such as IL-6, TNFα and IL-1.
These cytokines interact with their cognate receptors on muscle to activate the downstream
transcription factor NF-κB and induce sarcomere proteolysis. Experimentally, inhibiting NF-κB
signaling largely prevents cancer-induced muscle wasting, indicating its prominent role in muscle
atrophy. Resveratrol, a natural phytoalexin found in the skin of grapes, has recently been shown to
inhibit NF-κB in cancer cells, which led us to hypothesize that it might have a protective role in
cancer cachexia. Therefore, we investigated if daily oral resveratrol could protect against skeletal
muscle loss and cardiac atrophy in an established mouse model. We demonstrate resveratrol
inhibits skeletal muscle and cardiac atrophy induced by C26 adenocarcinoma tumors through its
inhibition of NF-κB (p65) activity in the skeletal muscle and heart. These studies demonstrate for
the first time the utility of oral resveratrol therapy to provide clinical benefit in cancer-induced
atrophy through the inhibition of NF-κB in muscle. These findings may have application in the
treatment of diseases with parallel pathophysiologies such as muscular dystrophy and heart failure.
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Cancer cachexia is a wasting syndrome that affects as many as 80% of cancer patients with
advanced disease 1–3. While cancer cachexia is estimated to be the cause of death in more
than 20% of all cancer patients, the morbidity and collapse in the quality of life affects
nearly all patients 2, 4, 5. Clinically, the manifestations of cancer cachexia are well
established and include loss of skeletal muscle mass and adipose tissue, anorexia, asthenia,
and anemia with considerable alterations in lipid, carbohydrate and protein
metabolism 2, 5, 6. Patients remain in a hypermetabolic state as the tumor burden increases,
due to the tumor production of catabolic pro-inflammatory cytokines 5
Cancer cachexia is a complex metabolic disorder which diminishes lean body mass in
response to increases in tumor-released inflammatory cytokines, including TNFα, IL1, and
IL-6 7, 8. These tumor derived cytokines interact with their receptors on striated muscle to
activate the transcription factor NF-κB to enhance muscle atrophy, by enhancing the
degradation of the sarcomere9–12. The accelerated protein degradation and proteolysis of the
contractile apparatus is mediated by the ubiquitin proteasome system, including specific
ubiquitin ligases in muscle such as muscle ring finger-1 (MuRF1)7, 13. Inflammatory
cytokine-driven NF-κB activation is central in muscle atrophy found in a number of diseases
including muscular dystrophy, heart failure, sepsis, and cancer 14–16. Pharmacologic and
genetic inhibition of NF-κB prevents ubiquitin-dependent muscle wasting 10, 17 and can lead
to retention of muscle mass, strength, and can promote muscle regeneration 18–20.
Consequently, inhibition of NF-κB activity has enormous potential for the prevention and
treatment of muscle atrophy.
Resveratrol, a natural phytoalexin found in the skin of grapes, has recently been shown to
have beneficial effects on a variety of disease processes, including hepatocellular
carcinoma21 and neurodegenerative disease 22. Resveratrol’s activity in these diseases has
been due, in part, to its ability to inhibit NF-κB nuclear translocation and accumulation. It
does this by primarily inhibiting IκB kinase (IKK), whose activation is necessary for NF-κB
activity. In the present study, we test the hypothesis that resveratrol treatment inhibits




The transplantable C-26 adenocarcinoma cells were maintained as previously
described 23, 24
Animals and Tumor Implantation
Ninety-six female CD2F1 mice aged 45 to 70 days (weight 19 to 22 grams) were obtained
from the Charles River Laboratories (Wilmington, MA) and randomly divided into four
groups: 1) control mice, 2) control mice treated with resveratrol (100 mg/kg, 200 mg/kg, or
500 mg/kg), 3) tumor-bearing mice, and 4) tumor-bearing mice treated with resveratrol (100
mg/kg, 200 mg/kg, or 500 mg/kg). On day 0, the mice selected to go in the tumor-bearing
groups were injected subcutaneously in the right flank with 150 µL (approximately 750,000
cells) of C-26 adenocarcinoma cells.
Treatment with Resveratrol
Trans-resveratrol (Cayman Chemical, Ann Arbor, MI, Catalog #70675) was solubulized in
1.5% methylcellulose./ 0.2% Tween-20 with vigorous vortexing. Beginning on day 6, mice
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received daily single oral treatment delivered intragastrically using a 20 g gavage needle.
Resveratrol treated mice received daily single gavage treatment of 100 mg/kg, 200mg/kg, or
500mg/kg resveratrol, while controls received a comparable treatment of 250 µl of vehicle
alone.
Body Composition Analysis
Prior to tumor injection, all animals underwent body composition analysis using quantitative
magnetic resonance systems (QMR) echo MRI (EchoMRI-100, Echo Medical Systems,
Houston TX).
Echocardiography
Echocardiography was performed on conscious mice using a Visual Sonics Vevo 770
ultrasound biomicroscopy system as previously described by our laboratory 25.
Total RNA isolation/Real Time PCR determination of mRNA Expression
Total RNA was isolated from flash frozen tissue using Trizol (Sigma Chemical, St. Louis,
MO), cDNA made using High Capacity cDNA Archive kit (Applied Biosystems). Semi-
quantitative RT-PCR was performed using an MJ Research Inc. Thermo Cycler (Waltham,
MA) and New England Biolab (Ipswich, MA) reagents using the primers detailed in
supplemental data.
NF-κB activity assay
Nuclear extracts were isolated from heart and gastrocnemius muscle immediately after
harvest and NF-κB activity determined according to the manufacturer’s protocol (Cayman
Chemical, Ann Arbor MI).
Additional materials and methods can be found in the supplemental data section.
Results
Resveratrol showed no evidence of drug induced toxicity at the levels used in this study
Pharmacological studies detailing the metabolism of resveratrol both in animal and humans
have been carried out, and all indicate rapid absorption, distribution, metabolism and
excretion of resveratrol 26, 27. After oral administration, wide tissue distribution in rats has
been observed after 24 hours and significantly decreases after 72 hours.28 Toxicological
studies have also been completed with tolerance of dosages as high as 700 mg/kg in rats 28
without toxic effects, and several Phase I clinical trials are underway at oral doses as high as
100 mg/kg/day in humans26, 28. We therefore dosed resveratrol orally at 100–500 mg/kg/day
in the present study. We monitored toxicity by histology and lethality throughout the study.
No events surrounding drug delivery were noted, including any obvious toxicity or lethality
caused by daily oral gavage of resveratrol 100–500 mg/kg/day. Additionally, we did not
observe any drug-induced hepatotoxicity or nephrotoxicity across all doses of resveratrol
delivery, as confirmed by a blinded, independent pathologist on histological examination
(Supplemental Figure 1).
Resveratrol protects against C26 adenocarcinoma-induced weight loss in mice
We assayed resveratrol’s ability to prevent cancer-induced skeletal and cardiac muscle
atrophy in the C26-adenocarcinoma mouse model29 previously described by our
laboratory 24. Cultured C26 adenocarcinoma cells were injected into the back flank where it
develops into a tumor and induces muscle wasting in CD2F1 mice within 2 weeks. In the
present study, tumors were palpable by day 6 after inoculation in the tumor bearing subset
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mice. On Day 17, at completion of the study, there were no significant differences in tumor
weights among all tumor bearing mice (Figure 1A). Tumor bearing mice had a mean weight
loss of 8.8±1.7% from their baseline weights, while control mice gained 2.1±1.8% over the
experimental period (Figure 1B), despite all groups having an equivalent food intake (Figure
1C). In contrast, mice challenged with tumors and treated with 200 mg/kg of resveratrol
gained weight similar to the control group. Mice treated with 500 mg/kg and challenged
with tumor also maintained their weight compared to tumor bearing mice (Figure 1B). Mice
with tumors treated with 100 mg/kg of resveratrol were not protected against the tumor-
induced cachexia, losing 4.6 ± 2.9% of their body weight from baseline. These findings
demonstrate that resveratrol at doses >/= 200 mg/kg protects against tumor-induced weight
loss in this mouse model.
To delineate if resveratrol had any independent affects on muscle mass, control mice
without tumor were treated with 100–500 mg/kg in parallel with treated mice challenged
with tumor. We found that non-tumor control mice treated with resveratrol alone exhibited
body weights equal to control mice at lower doses (100 mg/kg, 200 mg/kg). At the highest
dose tested (500 mg/kg), mice lost weight compared to age-matched controls (Figure 1B).
These findings demonstrate that 500 mg/kg resveratrol may cause some weight loss in the
absence of cachexia, while the lower levels (100–200 mg/kg) do not affect body weight.
None of the resveratrol doses tested cause an increase in muscle mass, suggesting that the
protective effects of resveratrol were not due to independent increases in muscle mass.
Resveratrol protects against cachexia-induced lean body and fat mass loss
Cancer cachexia is characterized by the loss of both skeletal muscle mass and adipose tissue
resulting from alterations in protein and lipid metabolism. 2, 5, 6 We next determined the
body composition of mice challenged with tumors in the presence or absence of resveratrol
by MRI body composition analysis to determine lean body mass (LBM) and fat mass (FM).
We identified that 200 and 500 mg/kg of resveratrol significantly protected against tumor-
induced loss of LBM and FM composition in tumor-bearing mice (Figure 2A and 2B).
Compared to controls, untreated tumor bearing mice lost 5.3% LBM (16.1 ± 0.3 vs. 17.1 ±
0.1 g) in contrast to resveratrol-treated tumor bearing mice, which were completely
protected (LBM (200 mg/kg)=17.4 ± 0.19 g ; LBM (500 mg/kg)=17.3 ± 0.3 g). Untreated
tumor bearing mice lost 33.3% of their limited FM, compared to control mice (1.80 ± 0.15
vs. 3.1 ± 0.10 g). Tumor-challenged mice treated with 200 and 500 mg/kg were significantly
protected (2.7 ± 0.36 g and 2.4 ± 0.17 g, respectively). Resveratrol treatment given to
control mice without tumors did not affect LBM or FM. Since resveratrol did not cause
increases in total body mass (including LBM and FM) in the absence of tumor, these studies
indicate that resveratrol protection against tumor induced weight loss is not due to its ability
to increase muscle weight, LBM, or FM by itself.
Resveratrol inhibits tumor-induced gastrocnemius and cardiac atrophy
Isolated quadriceps and the heart were collected and weighed immediately after harvest.
Tumor bearing mouse quadriceps weighted significantly less (~23%) than corresponding
quadriceps muscle from control mice (Figure 3A). Isolated quadriceps muscle from control
mice treated with 100 mg/kg, 200 mg /kg and 500 mg/kg resveratrol were not significantly
different from control mice (Figure 3A). In contrast, quadriceps muscle from tumor-
challenged mice treated with 200 mg /kg and 500 mg/kg resveratrol were significantly
higher (16.6 ± 6.5%, 10.3 ± 4.9%, respectively) than untreated tumor-challenged mice
(Figure 3A), suggesting that >= 200 mg/kg resveratrol protected against tumor-induced
skeletal muscle atrophy. Tumor-bearing mice demonstrated significant hind limb atrophy as
evidenced by a 12.2% loss of mass compared to non-tumor-bearing controls (Figure 3B). To
determine a more general effect on skeletal muscle, we also weighed hind limb mass. Hind
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limb muscle mass was preserved in resveratrol treated (200 and 500 mg/kg) tumor-bearing
animals as evidenced by significant differences in treated tumor-bearing mice having a 12.4
± 5.7% and 9.2 ± 4.3% higher mass, respectively, than untreated tumor challenged mice.
Resveratrol treatment in control mice did not significantly differ from control mice at all 3
doses tested.
Tumor bearing mice exhibited a significant loss of total heart weight compared to control
mice. Treatment with 200 and 500 mg/kg was protective against this 8.6% total heart weight
loss identified after 17 days of tumor burden (Figure 3C). Treatment of control mice with
100 mg/kg, 200 mg/kg, 500 mg/kg of resveratrol did not affect total heart weight (Figure
3C). To further characterize the effects of resveratrol on the heart, we performed in vivo
trans-thoracic echocardiography on conscious mice from control, tumor-challenged with and
without 500 mg/kg resveratrol (Figure 4A, 4B, Table 1). We identified that 17 days of tumor
burden induced a decrease in anterior and posterior wall of the left ventricle, reflecting the
cardiac atrophy identified by a decrease in heart weight / body weight ratio and relative wall
thickness (Figure 4). In our first set of studies, mice challenged with tumor and assayed by
echocardiography lost approximately 8.8% of their body weight after 17 days of tumor
(Figure 1B). However, in our echocardiography studies, they lost only 6.8% (=21.8–
20.4/21.8) (tumor vs. control, Table 1). This may be due to the sample size and tumor size
variation we seen in individual mice. Treatment of tumor challenged mice with 500 mg/kg
resveratrol completely prevented the decrease in anterior and posterior wall thickness
(Figure 4A, 4B, Table 1). Treatment of control mice with resveratrol did not affect baseline
LV wall thickness or heart weight (Figure 4A, Table 1), suggesting that protection
resveratrol afforded the heart was not drug induced increases in muscle mass, but more
likely due to an inhibition of the signaling pathways mediating cardiac atrophy.
Resveratrol inhibits NF-κB transcription factor activity in tumor induced skeletal muscle
and heart atrophy
The C-26 adenocarcinoma tumor induces cachexia through its release of TNFα, IL-1, IL-6,
which interact with their cognate receptors on muscle to activate the downstream
transcription factor NF-κB30–34, to induce cachexia and muscle atrophy. Recent studies
have demonstrated experimentally the dominant role of NF-κB in muscle
atrophy 18–20, 35, 36 and resveratrol’s ability to inhibit NF-κB in cancer cells 37. Therefore,
we investigated if resveratrol’s inhibition of tumor-induced gastrocnemius and heart atrophy
was due in part to its inhibition of NF-κB (Figure 5). We identified that nuclear bound NF-
κB (p65 subunit) activity was significantly elevated in tumor-induced gastrocnemius and
heart, and completely reversed in mice treated with the highest levels of resveratrol (200 mg/
kg and 500 mg/kg) (Figure 5A, 5B). Gastrocnemius muscle from untreated tumor bearing
mice had 30.5% higher mean NF-κB activity compared to control mice (Figure5A). A
significant decrease in NF-κB (p65) activity was seen in tumor bearing mice given 200 and
500 mg/kg of resveratrol (decreased 39% and 51%, respectively) (Figure5A). Treated
control mice also had a significant decrease in NF-κB (p65) activity after treatment with 200
and 500 mg/kg dosage (decreased 34%, and 41%, respectively) compared to untreated tumor
challenged mice, indicating that resveratrol decreased endogenous NF-κB activity induced
by tumor in skeletal muscle.
Analysis of the heart revealed that tumor challenge induced a 19% increase in NF-κB
activity compared to control hearts (Figure 5B). Treatment of tumor bearing mice with 200
and 500 mg/kg resveratrol significantly decreased NF-κB (p65) activity compared to tumor
challenged mice (21.6%, and 31.2%, respectively) (Figure 5B). Treatment with 200 and 500
mg/kg resveratrol induced a significant reduction in NF-κB (p65) activity in control mice
(18.7% and 33.8%, respectively) compared to untreated tumor challenged mice. Recent
studies have identified that NF-κB induction of E3 ubiquitin ligases regulate atrophy is
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skeletal muscle10, 11. Furthermore, our laboratory has determined a critical role of the
cardiac ubiquitin ligase muscle ring finger-1 (MuRF1) in cardiac atrophy 25. Specifically,
we identified that mice lacking MuRF1 were essentially unable to atrophy in response to
dexamethasone 25. This contrasts with skeletal muscle, where both MuRF1 and Atrogin-1
play a partial role in inhibiting skeletal muscle atrophy 13. We next focused our investigation
on how resveratrol’s inhibition of NF-κB might affect cardiac MuRF1 expression in vivo.
Resveratrol inhibits cardiac MuRF1 mRNA expression
Tumor challenge induced MuRF1 mRNA expression in the heart significantly (~20%) after
17 days of tumor (Figure 5C). While resveratrol treatment did not affect MuRF1 expression
in control animals, 200 and 500 mg/kg resveratrol significantly inhibited the tumor-induced
MuRF1 compared to tumor challenge alone (~25% and ~75%, respectively), reaching
MuRF1 mRNA levels significantly less than that found in control animals (Figure 5C).
Since MuRF1 plays a pivotal role in cardiac atrophy in vivo 25, and MuRF1 is regulated in
part by NF-κB 10, 11, these findings suggest one mechanism by which resveratrol inhibits
tumor-induced cardiac atrophy by the inhibition of NF-κB-induced MuRF1 expression in
vivo.
Discussion
The C26-adenocarcinoma model of cancer cachexia has been used over the last 3 decades
for research on the natural history of carcinomas and anti-tumor therapy, as recently
reviewed by Aulino, et al., 2010 29. Nearly 190 papers can be found by searching PubMed
for C26 cancer, many focusing on C26-induced cachexia 29. The C26-adenocarcinoma
model was established in 1975 in an effort to create models which could be used to test
biological- and chemo-therapies 38. It can be established in nude and SCID mice, as well as
wild type mice, suggesting that lymphocytes play little, if any, role in the pathophysiology
of tumor progression 31. The predominant mechanism by which the C26-adenocarcinoma
cell line induces cachexia is through its release of inflammatory cytokines 31, paralleling the
mechanism by which cancer causes cachexia in humans 8.
Initial studies of the C26-adenocarcinoma mouse model, as used in the present study,
identified a prominent role of IL-6 in the induction of muscle atrophy. In these studies,
inhibiting IL-6 using cytokine specific reagents prevented muscle atrophy induced in C26-
adenocarcinoma bearing mice. Additional studies identified that IL-6 was not the sole
mechanism for the induction of muscle cachexia 34, 39. The C26-adenocarcinoma cells were
also found to secrete TNFα, IL-1, and IL-6 in vivo, along with yet to be identified cachexia
factors that induce skeletal muscle atrophy in vivo 31, 33. These pro-inflammatory cytokines
bind to their cognate receptors found on skeletal muscle and heart, to activate the
transcription factor NF-κB 40, which mediates their downstream effects. The activation of
NF-κB is essential to the process of atrophy in striated muscle. This has been proven
convincing by using dominant negative inhibitory NF-κB complexes (IKK), which
effectively inhibits NF-κB. Over-expression of a dominant negative IKKα/β-EGFP fusion
protein, which inhibits NF-κB markedly inhibited disuse induced atrophy up to 70% in
vivo 17. Other studies have also identified that pharmacologic or genetic inhibition of IKK/
NF-κB similarly inhibits ubiquitin dependent muscle wasting (proteolysis) 10. In these
studies, NF-κB inhibition inhibited the expression of the ubiquitin ligase MuRF1, one of
two ubiquitin ligases that are necessary for skeletal muscle atrophy to occur 10.
Proinflammatory mediators, such as TNFα, are potent inducers of the ubiquitin ligase
MuRF1 13. Recent studies have shown that MuRF1 expression is regulated by the
transcription factor NF-κB 10, 41, which is activated by a number of proinflammatory
cytokines, including TNFα. Similarly, the C26-adenocarcinoma tumor in mice induces
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protein catabolism by inducing the ubiquitin ligase MuRF1 42. C26 burden induces specific
loss of thick, but not thin filament sarcomere components 24 and alters myosin isoform
expression 43, consistent with the actions of MuRF1 44. The dystrophin complex is
decreased in C26 adenocarcinoma-bearing mice, a phenomenon essential for muscle
degradation 42. This model has allowed the demonstration of the role of stem cells in
skeletal muscle during cachexia45, 46.
While MuRF1 plays only a partial role in mediating skeletal muscle atrophy in vivo 13, our
laboratory has recently identified that MuRF1 activity is necessary to induce ANY cardiac
atrophy 25. Specifically, we identified that the significant dexamethasone-induced atrophy
induced in wild type hearts is essentially absent in MuRF1 −/− mice 25. We therefore
focused our present studies on the ubiquitin ligase MuRF1 expression in the heart. We
hypothesized that resveratrol’s inhibition of cardiac NF-κB would reduce cardiac MuRF1
expression, representing one mechanism by which cardiac atrophy is inhibited in the C26-
adenocarcinoma-induced cachexia mouse model. In fact, we did identify that resveratrol
inhibited tumor-enhanced MuRF1 expression in vivo (Figure 5C). Therefore, our findings
are consistent resveratrol’s prevention of cardiac atrophy to be due, in part, to the inhibition
of MuRF1, possibly through its inhibition of NF-κB. However, MuRF1 is also regulated by
other transcription factors such as FOXO transcription factors 47–49, so it is possible that
resveratrol inhibits MuRF1 by mechanisms other than NF-κB in the heart. The findings in
the present study demonstrate resveratrol protects against cancer induced cardiac atrophy by
inhibiting NF-κB and MuRF1, suggesting one or more mechanisms by which it is
cardioprotective.
Cachexia in human cancer patients presents as muscle loss, often with the loss of fat
associated with anorexia, inflammation, and insulin resistance 50. Previous studies have
demonstrated that C26-adenocarcinoma induced cachexia induces a loss of both lean muscle
and fat, as we identified in the present study 51, 52. The details of how cachexia causes fat
loss has not been completely delineated, but increased expression of hormone-sensitive
lipase is a down-stream effect of factors secreted by tumors 50. While it might be possible
inflammatory cytokines and NF-κB may mediate this in muscle, not enough about these
complex signaling pathways in adipocytes is currently known to support this hypothesis 53.
One of the strengths of the current study is that resveratrol did not affect the C26-
adenocarcinoma tumor size, allowing us to determine the resveratrol’s efficacy specifically
at the level of skeletal muscle and heart. However, it is important to note that resveratrol has
been reported to inhibit tumor growth, including multiple myeloma cells (IM-9 cell line),
HELA cells (cervix carcinoma), and K-562 cells (chronic myeloid leukemia)37, 54, 55. In
fact, the efficacy of NF-κB inhibition by resveratrol to protect against skeletal muscle loss
induced by the MAC16 tumor (using 1 mg/kg/day) in a previous study by Wyke et al.56
could be attributed to its inhibition of tumor growth itself, making the present study unique
from a mechanistic point of view. The ability of resveratrol to inhibit tumor growth itself
may be of great benefit to patients with cachexia. Along with our present study, these
findings indicate that resveratrol protects against cancer cachexia by 2 distinct mechanisms:
1) by inhibiting tumor growth directly, inducing cell death resulting in a reduction of total
cytokine release; and 2) by inhibiting cytokine-driven NF-κB signaling at the level of the
skeletal muscle and heart. Since resveratrol does not affect the C26-adenocarcinoma tumor
in the present study, resveratrol may be even more potent then the results of the present
study demonstrate.
The contribution of cardiac complications in human cancer cachexia has not been studied
widely. However, many of the inflammatory mediators found cachexia are found in heart
failure and directly cause cardiac dysfunction, including IL-6, IL-1, and TNFα. The best
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studied is TNFα, which itself can induce heart failure and has been implicated in the
pathophysiology of a number of heart diseases 7. This suggests that cardiac involvement
may be common in cardiac cachexia, particularly in severe disease. Experimentally,
cachexia has been shown to induce heart failure, disrupt myocardial structure, and alter
composition of the contractile proteins in mouse models 43, 57. We did not identify gross
systolic dysfunction by echocardiography in the present study. However, larger tumors
forming over longer periods may have led to cardiac dysfunction in our model.
In the present study, we demonstrate for the first time that resveratrol directly inhibits
skeletal muscle and cardiac atrophy at oral doses of 200–500 mg/kg/day in a mouse model
of tumor-induced cachexia and cardiac atrophy without any apparent toxicity to the mouse.
A recent study performed by Busquets, et al. found that reseveratrol did not prevent cancer-
induced skeletal muscle wasting, using a rat model with Yoshida AH-130 ascites hepatoma
(treated with 1 mg/kg/day resveratrol intraperitoneally) or in mice bearing the Lewis lung
carcinoma (at 5 and 25 mg/kg/day resveratrol intraperitoneally)58. Rats were also given oral
resveratrol (3 mg/kg/day) in combination with fish oil intragastrically 58. Note that
significantly lower doses were used in the intragastric model compared to our present study
(100–500 mg/kg/day). The inability of resveratrol to protect against skeletal muscle mass or
body weight loss in tumor-bearing rodents may therefore be due to the lower doses of
resveratrol used in this earlier study. Consistent with this hypothesis, our use of 100 mg/kg/
day by oral gavage did not have any effect on muscle loss, while a dose of at least 200 mg/
kg/day was necessary to protect again tumor-induced cachexia. The effective doses in the
current mouse study are roughly 3 times the dose tested in humans without toxicity. In s
phase I clinical trial, a single dose of 5 g/day have been given to humans without obvious
toxicity. 26 In an average 70 kg person, this dose would be approximately 71 mg/kg/day
(5000 mg/70 kg), or approximately 2.8 times less than the minimum effective dose found in
the current studies (200 mg/kg/day vs. 71 mg/kg/day).
The effects of long term resveratrol exposure in the context of treating cancer cachexia in
the present model are not known. However, it should be pointed out that mice receiving 500
mg/kg/day (Figure 1B) lost weight in the presence or absence of tumor, whereas mice
receiving lower doses did not. Since these small, but significant changes were seen when
500 mg/kg/day was given over a short period of time (11 days), future studies should be
careful of the potential side effects with oral resveratrol therapy (i.e. weight loss) when
given at doses of 500 mg/kg/day. This would be particularly important in longer term studies
lasting greater than 11 days, which is likely how this drug would be used to treat cachexia in
patients.
Current therapies for cachexia include single modality therapy or combinations of
progestational agents, glucocorticoids, selective COX-2 inhibitors, or non-steroidal anti-
inflammatory drugs (NSAIDs) such as aspirin or indomethacin. Newer treatments have been
developed to inhibit cytokines or NF-κB to some degree. These include high dose
progestins59, eicosapentaenoic acid (EPA) 60, β-Hydroxy-β-methylbutyrate (HMB) 61,
thalidomide 62, and NSAID’s 63. However, these agents have adverse side effects and results
have been variable and marginal in reversing cachexia clinically. Resveratrol is currently
being used in a variety of human diseases, including hepatocellular carcinoma21 and
neurodegenerative disease 22 with no marked toxicity 7. It may therefore have application to
cachexia (including skeletal muscle and cardiac atrophy) and more broadly to heart failure in
a variety of contexts in human disease, although this has currently not been tested directly.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Non-standard abbreviations
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
IKK IκB kinase
MAC murine adenocarcinoma
LBM lean body mass
FM fat mass
MuRF1 muscle ring finger-1
UPS ubiquitin proteasome system
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Figure 1. Final tumor weights and average food intake
(A) There were no significant differences in tumor weights amongst tumor bearing groups at
all tumor weights and amongst the subset of tumors larger than 0.56 g at time of harvest
using unpaired t-tests. (B) Significant changes in carcass weight loss was seen in the
untreated tumor bearing mice compared to control mice, control mice receiving resveratrol
at all doses and tumor bearing mice receiving resveratrol at the 200 mg/kg and 500 mg/kg
doses. Carcass weight was determined by subtracting the weight of the tumor from the body
weight. Total carcass weights were analyzed and represented by the percentage change from
baseline among all groups. Also no significant differences were noted in (C) average food
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intake per mouse per day. n/s = no significance detected ## = p <0.0001, # = p <0.001, ** =
p < 0.01, * = p < 0.05. For (A) N=24 (Tumor), N=8 (Tumor +R100), N=7 (Tumor +R200),
N=8 (Tumor +R500). For (B) and (C) N=24 (Tumor), N=8 (Tumor +R100), N=7 (Tumor
+R200), N=8 (Tumor +R500).
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Figure 2. Final body composition among non-tumor bearing and tumor bearing mice
Whole mouse body composition was determined and graphed to show final mass in grams
among all groups. (A) Significant lean muscle mass loss was seen in the untreated tumor
bearing mice compared to control mice, control mice receiving resveratrol at all dosages and
tumor bearing mice receiving resveratrol at the 200 mg/kg and 500 mg/kg levels. (B) Fat
mass compositions were compared among the same subsets with significant fat mass loss
shown in the untreated tumor bearing group. The tumor bearing groups receiving resveratrol
showed significant responses by maintaining more fat mass in the 200 mg/kg and 500 mg/kg
groups. The untreated and treated control groups also were significantly higher in fat mass
composition compared to untreated tumor bearing. ## = p <0.0001, # = p <0.001, ** = p <
0.01, * = p < 0.05. For (A) and (B) N=24 (Tumor), N=8 (Tumor +R100), N=8 (Tumor
+R200), N=8 (Tumor +R500). For (C) N=17 (Tumor), N=6 (Tumor +R100), N=6 (Tumor
+R200), N=7 (Tumor +R500).
Shadfar et al. Page 15













Figure 3. Final weights among non-tumor bearing and tumor bearing mice
(A) Quadriceps were individually analyzed and significant weight loss was shown in the
untreated tumor bearing group compared to control, treated controls at all dosages, as well
as the treated tumor bearing groups at the 200 and 500 mg/kg doses. The 100 mg/kg treated
tumor bearing group was not significantly different in quadriceps weight from the non-
treated tumor bearing group.(B) The tumor bearing groups receiving resveratrol showed
significant responses by maintaining hindlimb weights comparable to control in the 200 mg/
kg and 500 mg/kg groups. The untreated and treated control groups also were significantly
higher in hindlimb weights compared to untreated tumor bearing mice. Hindlimb weights
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were compared among the same subsets with significant weight loss shown in the untreated
tumor bearing group. (C) Significant decreases in heart weight were seen in the untreated
tumor bearing mice compared to control mice, control mice receiving resveratrol at all doses
and tumor bearing mice receiving resveratrol at the 200 mg/kg and 500 mg/kg doses.
Change in heart weights among non-tumor bearing and tumor bearing mice. Individual
hearts were weighed and are graphically represented here to show heart weight as a
percentage of average control heart weight among all groups. ## = p <0.0001, # = p <0.001,
** = p < 0.01, * = p < 0.05. For (A)-(C) N=24 (Control), N=8 (Control +R100), N=8
(Control + R200), N=8 (Control +R500), N=17 (Tumor), N=6 (Tumor + R100), N=6
(Tumor + R200), N=7 (Tumor +R500).
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Figure 4. Resveratrol protects against tumor induced cardiac atrophy
(A) Conscious echocardiography of the left ventricle indentified significant decreases in
tumor-induced anterior and posterior wall thickness in diastole, heart weight to body weight
ratio (HW/BW), and relative wall thickness, that were not identified when 500 mg/kg/day
resveratrol was given. (B) Representative M-mode recordings from images used in the
analysis of (A). A one-way ANOVA was performed to determine significance, followed by
a Holm-Sidak pairwise comparison to significance between groups. *p<0.05. BW, body
weight, HW, heart weight; RWT=LVPW;d/s+LVAntW; d/s / LVEDD or LVEDS; LV mass
(index)=[1.055* ( (ExLVD;d)3- (LVEDD;d)3). N=4 per group.
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Figure 5. Nuclear factor-kappa B activity (p65)
(A) Nuclear extractions on gastrocnemius muscle were analyzed looking at p65 bound DNA
activity. Significant increase in activity was noted in untreated tumor bearing mice
compared to control. Tumor bearing mice treated with resveratrol showed a significant
decrease in NF-κB activity at 200 mg/kg and 500 mg/kg dosages. Also of note in the treated
non-tumor bearing group NF-κB activity was significantly decreased and comparable to
control with administration of resveratrol at the 200 mg/kg and 500 mg/kg dosages. (B) The
tumor bearing groups receiving 200 mg/kg and 500 mg/kg resveratrol showed significant
inhibition of tumor-induced NF-κB activity. (C) Tumor bearing mice receiving 200 mg/kg
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and 500 mg/kg resveratrol had an inhibition of tumor-induced MuRF1 expression. mRNA
expression was measured and depicted here as normalized to GAPDH controls. # = p
<0.001, ** = p < 0.01, * = p < 0.05. For (A) and (B): N=12 (Control); N=4 (Control +
R100), N=4 (Control + R200), N=4 (Control + R500), N=4 (Tumor), N=4 (Tumor +R200),
N=4 (Tumor + R500). For (C): N=4 (Control), N=3 (Control + R100), N=3 (Control +
R200), N=3 (Control + R500), N=4 (Tumor), N=3 (Tumor +R100), N=3 (Control + R200),
N=3 (Control +R500).
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Table 1
Transthoracic echocardiography on unanesthetized sham, tumor, or tumor plus
resveratrol treatment in age-matched mice 16 days after tumor implantation (±SE)











Body Weight (g) 21.8 ± 0.4 20.4 ± 1.1 21.6 ± 0.8 20.6 ± 0.4
HR (bpm) 651 ± 9 617 ± 27 640 ± 13 659 ± 13
LVEDD (mm) 2.63 ± 0.09 2.95 ± 0.08* 2.82 ± 0.13 2.50 ± 0.07
LVESD (mm) 1.11 ± 0.05 1.35 ± 0.07 1.19 ± 0.10 1.08 ± 0.06
LV %EF 88.97 ± 0.46 85.78 ± 2.78 88.64 ± 1.86 88.20 ± 0.94
LV Vol; d (ml) 25.9 ± 2.2 33.8 ± 2.2 30.6 ± 3.5 22.8 ± 1.5
LV Vol; s (ml) 2.9 ± 0.3 4.7 ± 0.7 3.5 ± 0.8 1.7 ± 1.5
BW, body weight; LV, left ventricle; HR, heart rate; LVEDD, LV end diastolic dimension; LVESD, LV end systolic dimension; LV EF%=[ (LV
Vol;d-LV Vol;s/LV Vol;d )*100];LV Vol; d, LV volume in diastole; LV Vol;s, LV volume in systole; LV Post W.
*
p<0.05 vs Control, Tumor + 500R, and Control + 500R.
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